

Daide Greco<sup>1,2</sup>, A. Iacono<sup>1,2</sup>, S. Valente<sup>1,2</sup>, F. Piattellini<sup>1,2</sup>, G. Grigioni<sup>2</sup>, L. Caremani<sup>2</sup>, A. Govoni<sup>2</sup>, M. Massei<sup>2</sup>, V. Ambrogi<sup>2</sup>, R. Capelli<sup>2</sup>, S. Ramat<sup>2</sup>

1 Department of Neurosciences, Psychology, Pharmacology and Child Health, University of Florence, Florence, Italy.

2 Parkinson Unit, Department of Neuroscience and Sensorial Organs, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.

## Introduction

In the complex phase of Parkinson's Disease (PD), patients may experience motor and non-motor fluctuations not controlled by oral therapy, with significant impact on quality of life. Continuous subcutaneous infusion of foslevodopa/foscariodopa (CSFLI), recently approved, has proven to be a good strategy for controlling fluctuations and complications of the disease, ensuring a stable plasma concentration of levodopa over time.

## Materials and Methods

- **Study sample:** 20 subjects with advanced PD
- **Clinical assessment:** six-monthly clinical evaluations over the course of 1 year
- **Scales:** Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Unified Dyskinesia Rating Scale (UdysRS), Parkinson's Disease Quality of Life Questionnaire 39 (PDQ-39), Hamilton Rating Scale for Depression (HDRS), Parkinson's Disease Sleep Scale 2 PDSS-2).

## Objective

To assess CSFLI efficacy and tolerability in a real-life setting

### Up to October 2025

- 12 subjects completed 6 months follow-up
- 7 subjects completed 12 months follow-up
- 4 drop out
- Duration of disease at baseline (years)
  - mean 13.8
  - range (6-25)

## Results

Figure 1. UPDRS scores (I-IV) in patients who completed 6 months follow-up





Figure 2. UPDRS scores (I-IV) in patients who completed 12 months follow-up



\*N.B. Unless otherwise specified, the values of the UPDRS II and III are reported in ON-medication state




Figure 3. PDSS-2, HRDS, PDQ-39, UdysRS I scores in patients who completed 12 months follow-up

## Side effects

- A total of 15 events in 7 patients
- 12 of them were related to the infusion site
- 2 of them had hallucinations, resolved with reduction of infusion rate
- None of the side effects led to discontinuation of therapy

## Discontinuation of therapy

- 3 patients discontinued for lack of compliance
- In one case CSFLI was a bridging therapy before deep brain stimulation

## Conclusions

Despite the limitations linked to the small study sample and the short duration of follow up, our data demonstrate good tolerability and efficacy of CSFLI in controlling complex-stage complications while improving the patient's quality of life.